Conclusions/interpretation Both SGLT2is and GLP-1 RAs have potential benefits as adjunctive agents in type 1 diabetes
The results are consistently positive and the mechanistic data is compelling, but as of 2026 there are no completed Phase 3 human randomized controlled trials
however, our office will provide guidance on managing these effects to ensure a smoother experience
For health authorities, these developments raise pressing questions about oversight, misuse and patient safety
Documentation Data Sheet (236 KB) SDS (251 KB) English - EN (251 KB) Franais - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Espaol - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB) Handling Instructions (2659 KB) Calculators Concentration (start) Volume (start) = Concentration (final) Volume (final)
Brightens, smooths, firms, and protects your skin